LearnGlossaryMarketStocksSuperinvestorsSign in

TWST

Twist Bioscience Corporation

Healthcare · $7.8B market cap

Verdict

We can't put a fair value on TWST right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-1.3% a year✗
Sales growth36.5% a year✓
Free cash flow growth—?
Return on invested capital-31.3%✗

Follow TWST

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds TWST. In Q2 2026, 1 added. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$5.7M

55,310 shares

Moves in Q2 2026

Added: Polen Capital Management

Insider activity

Since Sep 8, 2026: no open-market purchases and 4 sales worth $473K. Why purchases matter

Sales

WERNER ROBERT F.

Chief Accounting Officer · 2026-09-08

Sold

$29K

Leproust Emily M.

Chief Executive Officer · 2026-09-08

Sold

$282K

Green Paula

SVP of Human Resources · 2026-09-08

Sold

$111K

Cho Dennis

See Remarks · 2026-09-08

Sold

$51K

About Twist Bioscience Corporation

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works